Anti-TF monoclonal antibody - NEMOD

Drug Profile

Anti-TF monoclonal antibody - NEMOD

Alternative Names: KaroMab™

Latest Information Update: 15 Feb 2008

Price : $50

At a glance

  • Originator NEMOD Biotherapeutics [CEASED]
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 06 Apr 2006 No development reported - Preclinical for Cancer in Germany (Injection)
  • 25 Aug 2004 KaroMab™ is available for licensing
  • 26 Jun 2003 Preclinical trials in Cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top